Scan to downloadASKA Pharmaceutical Holdings CO., Ltd. (4886) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-11-04 | — | ASKA Pharmaceutical Enters into License Agreement for MHB018A for the Treatment of Thyroid Eye Disease (TED) | |
| 2026-11-04 | Earnings Release | Supplementary Documents of Consolidated Financial Results for the Second Quarter of FY2026 | |
| 2026-11-04 | Earnings Release | Summary of Financial Results for the First Half (Interim Period) of the Fiscal Year Ending March 31, 2027 (Japanese GAAP) (Consolidated) | |
| 2026-11-02 | Treasury Shares | Completion of Payment for Disposal of Treasury Shares as Restricted Stock Incentives for the Employee Stock Ownership Association and Partial Forfeit | |
| 2026-08-12 | Treasury Shares | Notice Concerning Completion of Payment for Disposal of Treasury Shares as Remuneration for Restricted Shares | |
| 2026-08-04 | Earnings Release | Summary of Consolidated Financial Results for the First Quarter of FY2026 | |
| 2026-08-04 | Earnings Release | Supplementary Documents of Consolidated Financial Results for the First Quarter of FY2026 | |
| 2026-07-13 | Treasury Shares | Notice Concerning Disposal of Treasury Shares as Remuneration for Restricted Stock | |
| 2026-07-13 | Treasury Shares | Notice Concerning Disposal of Treasury Shares for Restricted Stock Incentives to the Employee Shareholding Association |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.